Breast
Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
Rugo HS, Bardia A, Gradishar WJ, et al.
The REal-world TReatment patterns And Considerations of Toxicity in HR+/HER2-mBC (RETRACT) survey was designed to evaluate real-world practice patterns in disease testing and management. Based on responses from 150 US oncologists, most practice in accordance with guidelines; however, there were exceptions for substantial minorities related to the definition and treatment of visceral crisis, treatment for patients with endocrine resistance, routine use of next-generation sequencing for biomarker testing, and prophylactic measures for treatment-related adverse events in patients receiving alpelisib.
Previous Article
- • Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan
- • The Safety and Effectiveness of Palbociclib in Clinical Practice
- • Determinants of HER2-Targeted Therapy Use in Metastatic HR-/HER2+ Breast Cancer
- • Equity of Care Across Metastatic Breast Cancer Treatment
- • Tumor Growth Rate and Survival in Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- • Patient-Reported Outcomes From DESTINY-Breast04
- • Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
- • Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
- • Animal Models in Metastatic Breast Cancer Immunotherapy Research
- • PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
- • Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
- • Imlunestrant Monotherapy: Phase 1a/1b EMBER Study
- • Characterization of Imlunestrant as an Oral, Brain-Penetrant SERD
- • Pharmacodynamics from EMBER-2
- • Imlunestrant: First Approval
- • Imlunestrant Overcomes ESR1 Mutant Resistance in ER-Positive Breast Cancer
- • ESR1 Mutations in Breast Cancer
